Triple hormone contraceptive - ANI Pharmaceuticals/Pantarhei

Drug Profile

Triple hormone contraceptive - ANI Pharmaceuticals/Pantarhei

Alternative Names: Androgen Restored Contraceptive; ARC; Triple OC

Latest Information Update: 20 Oct 2015

Price : $50

At a glance

  • Originator BioSante Pharmaceuticals
  • Developer ANI Pharmaceuticals; Pantarhei Bioscience
  • Class Androstenes; Androstenols; Antiandrogens; Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Pregnancy
  • No development reported Female sexual dysfunction

Most Recent Events

  • 20 Oct 2015 Phase-II/III clinical trials in Pregnancy (prevention) in Netherlands (PO)
  • 10 Jun 2015 No recent reports on development identified - Clinical-Phase-Unknown for Pregnancy (prevention) in USA (Transdermal)
  • 10 Jun 2015 No recent reports on development identified - Phase-II/III for Contraception and Female sexual dysfunction in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top